Press releases

19 May 2019

UCB announces NAYZILAM® (midazolam) nasal spray now approved by FDA to treat intermittent, stereotypic episodes of frequent seizure activity in people living with epilepsy in the U.S.

2 May 2019

Transparency notifications BlackRock, Inc.

25 Apr 2019

UCB's General Meeting of Shareholders

24 Apr 2019

New Data Showcases the Value of CIMZIA® (certolizumab pegol) in Patients with Psoriasis 

10 Apr 2019

Transparency notification BlackRock, Inc.

9 Apr 2019

FDA Approves Evenity™ (Romosozumab) For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture

Press releases

Press releases

Search Press releases

UCB announces NAYZILAM® (midazolam) nasal spray now approved by FDA to treat intermittent, stereotypic episodes of frequent seizure activity in people living with epilepsy in the U.S.

Transparency notifications BlackRock, Inc.

UCB's General Meeting of Shareholders

New Data Showcases the Value of CIMZIA® (certolizumab pegol) in Patients with Psoriasis

Transparency notification BlackRock, Inc.

FDA Approves Evenity™ (Romosozumab) For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture

Choose a Country

UCB Belgium: A global hub of healthcare innovation

Publications - A dedicated space where we share a collection of our scientific peer-reviewed...

Pipeline - Check out our clinical development pipeline spanning several therapy areas

Hidradenitis Suppurativa – Learn more about Hidradenitis Suppurativa an inflammatory skin disease

WoCBA - Closing the gaps in research in the care of women of childbearing age with chronic diseases

Clinical studies – Click to find out more on our clinical studies

Sustainability – Click here to learn more about our sustainable approach

UCBCares® - Discover what UCBCares® is about and the services they offer

Advancing Our Gene Therapy Journey

UCB receives U.S. FDA approval for BIMZELX[®] (bimekizumab-bkzx) as the first IL-17A and IL-17F...

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant...

UCB completes sale of established brands and updates 2024 financial guidance

UCB completes sale of established brands and updates 2024 financial guidance

Half-year results 2024: strong start into UCB’s decade of growth

Download center – Click here to view a collection of useful documents

Press releases

Search Press releases

UCB announces NAYZILAM® (midazolam) nasal spray now approved by FDA to treat intermittent, stereotypic episodes of frequent seizure activity in people living with epilepsy in the U.S.

Transparency notifications BlackRock, Inc.

UCB's General Meeting of Shareholders

New Data Showcases the Value of CIMZIA® (certolizumab pegol) in Patients with Psoriasis&nbsp;

Transparency notification BlackRock, Inc.

FDA Approves Evenity™&nbsp;(Romosozumab) For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture

Choose a Country

New Data Showcases the Value of CIMZIA® (certolizumab pegol) in Patients with Psoriasis

FDA Approves Evenity™ (Romosozumab) For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture